Pimavanserin | ACP-103 | 5-HT2A Inverse Agonist | AmBeed-信号通路专用抑制剂

首页 / 抑制剂/激动剂 / / 5-羟色胺受体 / Pimavanserin

匹莫范色林 /Pimavanserin 99%+

货号：A754938 同义名： ACP-103

Pimavanserin is a potent and selective 5-HT2A receptor inverse agonist with mean pIC50 of with 8.7 in the cell-based functional assay.

Pimavanserin 化学结构
CAS号：706779-91-1

Pimavanserin 3D分子结构
CAS号：706779-91-1

规格	价格	会员价	库存	数量
{[ item.pr_size ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]}	{[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]}	现货	咨询	- +

购物车0 收藏询单

sales@ambeed.cn tech@ambeed.cn 400-920-2911 产品手册产品订购技术咨询
快速发货顺丰冷链运输，1-2 天到达

品质保证

技术支持

免费溶解

Pimavanserin 纯度/质量文件产品仅供科研

货号：A754938 标准纯度： 99%+ 产品说明书

批次查询：批次纯度: COA SDS NMR HPLC CNMR LC-MS

全球学术期刊中引用的产品: • Cell,2024. Ambeed. [ A125712 ]; • Cancer Discov., 2024. Ambeed. [ A285925 ]; • JMC, 2024. Ambeed. [ A288696 ]; • JMC, 2024. Ambeed. [ A524399 , A633512 , A144280 , A174613 ]; • EJNMMI Radiopharm. Chem., 2024, 9, 61. Ambeed. [ A1257961 , A622068 ]; 更多 >

5-羟色胺受体亚型比较

产品名称	5-HT ↓ ↑	5-HT1 ↓ ↑	5-HT2 ↓ ↑	5-HT3 ↓ ↑	5-HT5 ↓ ↑	5-HT6 ↓ ↑	5-HT7 ↓ ↑	其他靶点	纯度
Desvenlafaxine	++ 5-HT, Ki: 40.2 nM								98%
Lamotrigine	+ 5-HT (human platelets), IC50: 240 μM 5-HT (rat brain synaptosomes), IC50: 474 μM								99%+
Venlafaxine	✔								99%+
Fluvoxamine maleate	✔								99%
Iloperidone	✔								99%+
Ziprasidone HCl	✔								98+%
Atomoxetine HCI	+ 5-HT, Ki: 77 nM								98%
Dapoxetine HCl	✔								99%+
Trazodone	✔								98+%
Clomipramine HCl	✔								99%+
Mirtazapine	✔								99+%
Escitalopram oxalate	+++ 5-HT, Ki: 0.89 nM								99%+
Duloxetine	✔								98+%
Sertraline HCl	++ 5-HT, Ki: 13 nM								99%+
Citalopram HBr	+++ serotonin reuptake, IC50: 1.8 nM								99%+
Latrepirdine 2HCl	✔							GluR	99%+
Fluoxetine hydrochloride	✔								98%
Paroxetine hydrochloride	✔							AChR	99%+
BMY 7378		++ 5-HT1A, pIC50: 6.4 5-HT1D, pIC50: 5.9	+ 5-HT2, pIC50: 5.5						97%
Flibanserin		+++ 5-HT1A, Ki: 1 nM	+ 5-HT2A, Ki: 49 nM						98%
LY310762		+ 5-HT1D, Ki: 249 nM							99%+
Cyclobenzaprine HCI			✔						99%
Blonanserin			+++ 5-HT2, Ki: 3.98 nM						99%+
Cyproheptadine HCl			++++ 5-HT2, IC50: 0.6 nM						99+%
Olanzapine			✔						99+%
Pimavanserin hemitartrate			+++ 5-HT2A, pIC50: 8.7						99%
Ketanserin			+++ 5-HT2C (Rat), Ki: 50 nM 5-HT2C (Human), Ki: 2.5 nM						99%+
Loxapine succinate			++ 5-HT2 (human), Ki: 6.8 nM 5-HT2 (bovine), Ki: 6.6 nM						99%
Agomelatine			✔						99%+
Clozapine			✔						99%+
Amitriptyline			+ 5-HT2, Ki: 235 nM					SERT	98%
PRX-08066 maleate			+++ 5-HT2B, IC50: 3.4 nM						98+%
RS-127445			++++ 5-HT2B, pIC50: 10.4 5-HT2B, pKi: 9.5						99%+
Sarpogrelate HCl			++++ 5-HT2A, Kd: 2.1 nM 5-HT2C, Kd: 1.1 nM						98%
Tropisetron				✔					99%
Palonosetron				✔					98+%
Ramosetron HCl				++++ 5-HT3 receptor, Ki: 0.091 nM					99%+
Ondansetron				✔					99%
Granisetron				✔					98%
Alosetron HCl				✔					98%
Ondansetron hydrochloride dihydrate				✔					99%+
VUF10166				++++ 5-HT3A, Ki: 0.04 nM 5-HT3AB, Ki: 22 nM					99%+
Azasetron hydrochloride				++++ 5-HT3, IC50: 0.33 nM					98%
Asenapine maleate		+++ 5-HT1B, pKi: 8.4 5-HT1A, pKi: 8.6	++++ 5-HT2A, pKi: 9.75 5-HT2C, pKi: 10.46		+++ 5-HT5A, pKi: 8.84	++++ 5-HT6, pKi: 9.6	++++ 5-HT7, pKi: 9.94		99%+
Risperidone		++ 5-HT1D, Ki: 84.6 nM 5-HT1B, Ki: 14.9 nM	++++ 5-HT2C, Ki: 12 nM 5-HT2A, Ki: 61.9 nM		+ 5-HT5A, Ki: 206 nM		++ 5-HT7, Ki: 6.6 nM		99%+
SB 271046 HCl						+++ 5-HT6, pKi: 8.92			99%+
Intepirdine						++++ 5-HT6, pKi: 9.63			99%+
SB-269970 HCl							++ 5-HT7, pKi: 8.3		98+%
BRL 15572		++ 5-HT1B, pKi: 6.1 5-HT1D, pKi: 6	++ 5-HT2A, pKi: 6.6 5-HT2B, pKi: 6.2			+ 5-HT6, pKi: 5.9	+ 5-HT7, pKi: 6.3		98%
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

Pimavanserin 生物活性

描述	Pimavanserin is a potent and selective 5-HT2A receptor inverse agonist with mean pIC50 of with 8.7 in the cell-based functional assay.

Pimavanserin 临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点
NCT00086294	Parkinson's Disease ... 展开 >> Dyskinesias 收起 <<	Phase 2	Completed	-	United States, Maryland ... 展开 >> National Institutes of Health Clinical Center, 9000 Rockville Pike Bethesda, Maryland, United States, 20892 收起 <<
NCT03152292	-		Recruiting	September 2021	-
NCT00087542	Hallucinations ... 展开 >> Psychoses Parkinson's Disease 收起 <<	Phase 2	Completed	-	United States, California ... 展开 >> Fountain Valley, California, United States, 92708 Sunnyvale, California, United States, 94089 United States, Connecticut Danbury, Connecticut, United States, 06810 United States, Florida Pompano Beach, Florida, United States, 33060 Tampa, Florida, United States, 33606 United States, Georgia Atlanta, Georgia, United States, 30329 United States, Kansas Kansas City, Kansas, United States, 66160 United States, Maryland Elkridge, Maryland, United States, 21075 United States, New York Albany, New York, United States, 12205 United States, North Carolina Asheville, North Carolina, United States, 28806 United States, Pennsylvania Philadelphia, Pennsylvania, United States, 19107 United States, Rhode Island Pawtucket, Rhode Island, United States, 02860 United States, Tennessee Brentwood, Tennessee, United States, 37027 收起 <<

Pimavanserin 参考文献

[1]Vanover KE, Betz AJ, et al. A 5-HT2A receptor inverse agonist, ACP-103, reduces tremor in a rat model and levodopa-induced dyskinesias in a monkey model. Pharmacol Biochem Behav. 2008 Oct;90(4):540-4.

[2]Vanover KE, Weiner DM, et al. Pharmacological and behavioral profile of N-(4-fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)phen ylmethyl) carbamide (2R,3R)-dihydroxybutanedioate (2:1) (ACP-103), a novel 5-hydroxytryptamine(2A) receptor inverse agonist. J Pharmacol Exp Ther. 2006 May;317(2):910-8.

Pimavanserin 实验方案

计算器

存储液制备

1mg

5mg

10mg

1 mM

5 mM

10 mM

2.34mL

0.47mL

0.23mL

11.69mL

2.34mL

1.17mL

23.39mL

4.68mL

2.34mL

Pimavanserin 技术信息

CAS号	706779-91-1
分子式	C₂₅H₃₄FN₃O₂
分子量	427.555

别名	ACP-103
运输	蓝冰

存储条件

粉末 Sealed in dry,Room Temperature

液体 -20°C:3-6个月-80°C:12个月

溶解度

DMSO: 50 mg/mL(116.94 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO

动物实验配方

临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点

NCT00086294	Parkinson's Disease ... 展开 >> Dyskinesias 收起 <<	Phase 2	Completed	-	United States, Maryland ... 展开 >> National Institutes of Health Clinical Center, 9000 Rockville Pike Bethesda, Maryland, United States, 20892 收起 <<
NCT03152292	-		Recruiting	September 2021	-
NCT00087542	Hallucinations ... 展开 >> Psychoses Parkinson's Disease 收起 <<	Phase 2	Completed	-	United States, California ... 展开 >> Fountain Valley, California, United States, 92708 Sunnyvale, California, United States, 94089 United States, Connecticut Danbury, Connecticut, United States, 06810 United States, Florida Pompano Beach, Florida, United States, 33060 Tampa, Florida, United States, 33606 United States, Georgia Atlanta, Georgia, United States, 30329 United States, Kansas Kansas City, Kansas, United States, 66160 United States, Maryland Elkridge, Maryland, United States, 21075 United States, New York Albany, New York, United States, 12205 United States, North Carolina Asheville, North Carolina, United States, 28806 United States, Pennsylvania Philadelphia, Pennsylvania, United States, 19107 United States, Rhode Island Pawtucket, Rhode Island, United States, 02860 United States, Tennessee Brentwood, Tennessee, United States, 37027 收起 <<
NCT00361166	Schizophrenia	Phase 2	Completed	-	United States, California ... 展开 >> Cerritos, California, United States, 90703 Garden Grove, California, United States, 92845 Glendale, California, United States, 91206 Paramount, California, United States, 90723 Pico Rivera, California, United States, 90660 San Diego, California, United States, 92123 San Diego, California, United States, 92126 United States, District of Columbia Washington, District of Columbia, United States, 20016 United States, Missouri St. Louis, Missouri, United States, 63118 United States, Texas Austin, Texas, United States, 78756 Irving, Texas, United States, 75062 Brazil Salvador, BA, Brazil, 40325-090 Aparecida de Goiânia, GO, Brazil, 74922-810 Curitiba, PR, Brazil, 80430-050 Curitiba, PR, Brazil, 80520-000 Rio de Janeiro, RJ, Brazil, 21020-130 São Paulo, SP, Brazil, 05403-010 收起 <<
NCT03661125	Parkinson Disease Psychosis	Early Phase 1	Not yet recruiting	September 1, 2021	United Kingdom ... 展开 >> Mitul Mehta Not yet recruiting London, Camberwell, United Kingdom, SE5 8AF Contact: Mitul Mehta +44 (0)2032283053 mitul.mehta@kcl.ac.uk Contact: Miriam Vignando 07492634351 miriam.vignando@kcl.ac.uk 收起 <<
NCT00658567	Parkinson's Disease Psychosis	Phase 3	Completed	-	-
NCT01518309	Parkinson's Disease Psychosis	Phase 2	Completed	-	United States, Connecticut ... 展开 >> Danbury, Connecticut, United States, 06810 收起 <<
NCT00477672	Parkinson's Disease Psychosis	Phase 3	Completed	-	-
NCT00477672	-		Completed	-	-
NCT00550238	Parkinson's Disease Psychosis	Phase 3	Completed	-	-
NCT03325556	Dementia-related Psychosis	Phase 3	Recruiting	March 2020	-
NCT00658567	-		Completed	-	-
NCT01174004	-		Completed	-	-
NCT01174004	Parkinson's Disease Psychosis	Phase 3	Completed	-	-
NCT03575052	Neuropsychiatric Symptoms Rela... 展开 >>ted to Neurodegenerative Disease 收起 <<	Phase 3	Recruiting	May 2021	United States, California ... 展开 >> Syrentis Clinical Research Recruiting Santa Ana, California, United States, 92705 United States, Florida Indago Research & Health Center Inc Recruiting Hialeah, Florida, United States, 33012 Future Care Solution, LLC Recruiting Miami, Florida, United States, 33165 Laszlo J Mate, MD, PA Recruiting North Palm Beach, Florida, United States, 33408 University of South Florida Recruiting Tampa, Florida, United States, 33613 Bioclinica Research Recruiting The Villages, Florida, United States, 32162 United States, Massachusetts Boston Center Memory Recruiting Newton, Massachusetts, United States, 02459 United States, New Jersey The NeuroCognitive Institute Recruiting Mount Arlington, New Jersey, United States, 07856 United States, New York Parker Jewish Institute for Health Care & Rehabilitation Recruiting New Hyde Park, New York, United States, 11040 United States, North Carolina UNC Hospital Not yet recruiting Chapel Hill, North Carolina, United States, 27599 United States, Ohio Insight Clinical Trials LLC Recruiting Shaker Heights, Ohio, United States, 44122 United States, Pennsylvania Suburban Research Associates Recruiting Media, Pennsylvania, United States, 19063 Georgia Petre Sarajishvili Institute of Neurology LLC Recruiting Tbilisi, Georgia, 0112 Pineo Medical Ecosystem LTD Recruiting Tbilisi, Georgia, 0114 Health Institute LLC Recruiting Tbilisi, Georgia, 0160 S. Khechinashvili University Hospital LLC Recruiting Tbilisi, Georgia, 0179 收起 <<
NCT02992132	Agitation and Aggression in Al... 展开 >>zheimer's Disease 收起 <<	Phase 2	Completed	-	-
NCT02035553	Alzheimer's Disease Psychosis	Phase 2	Completed	-	United Kingdom ... 展开 >> London, United Kingdom 收起 <<
NCT02970305	Schizophrenia	Phase 2	Recruiting	June 2019	-
NCT02762591	-		-	-	-
NCT03018340	Adjunctive Treatment of Major ... 展开 >>Depressive Disorder 收起 <<	Phase 2	Completed	-	-
NCT02970292	Schizophrenia	Phase 3	Recruiting	January 2019	-
NCT02035553	-		Completed	-	-
NCT03118947	Agitation and Aggression in Al... 展开 >>zheimer's Disease 收起 <<	Phase 2	Active, not recruiting	August 2019	-
NCT03482882	Treatment of Depression in Adu... 展开 >>lts With Parkinson's Disease (PD) 收起 <<	Phase 2	Recruiting	May 2019	United States, California ... 展开 >> ATP Clinical Research, Inc. Recruiting Costa Mesa, California, United States, 92626 The Parkinson's and Movement Disorder Institute Recruiting Fountain Valley, California, United States, 92708 SC3 Research-Reseda Recruiting Pasadena, California, United States, 91105 The Neurology Group Recruiting Pomona, California, United States, 91767 SC3 Research-Reseda Recruiting Reseda, California, United States, 91335 CNS Network Recruiting Torrance, California, United States, 90502 United States, Connecticut Associated Neurologists, P.C. Recruiting Danbury, Connecticut, United States, 06810 United States, Florida Parkinson's Disease and Movement Disorder Center of Boca Raton Recruiting Boca Raton, Florida, United States, 33486 University of Florida Recruiting Gainesville, Florida, United States, 32607 Parkinson's Disease Treatment Center of SW Florida Recruiting Port Charlotte, Florida, United States, 33980 Infinity Clinical Research, LLC Recruiting Sunrise, Florida, United States, 33351 Tallahassee Neurological Clinic, P.A. Recruiting Tallahassee, Florida, United States, 32308 United States, Missouri Washington University School of medicine Recruiting Saint Louis, Missouri, United States, 63110 United States, New Jersey Bio Behavioral Health Recruiting Toms River, New Jersey, United States, 08755 United States, New York Albany Medical College Recruiting Albany, New York, United States, 12208 David L. Kreitzman, MD, PC Recruiting Commack, New York, United States, 11725 United States, North Carolina Asheville Neurology Specialists, PA Recruiting Asheville, North Carolina, United States, 28806 United States, Pennsylvania Neurology/Neurophysiology Recruiting Johnstown, Pennsylvania, United States, 15904 United States, Washington Booth Gardner Parkinson's Care Center Recruiting Kirkland, Washington, United States, 98034 Inland Northwest Research Recruiting Spokane, Washington, United States, 99202 收起 <<
NCT03623321	Neuropsychiatric Symptoms Rela... 展开 >>ted to Neurodegenerative Disease 收起 <<	Phase 3	Recruiting	January 2022	United States, California ... 展开 >> Syrentis Clinical Research Recruiting Santa Ana, California, United States, 92705 United States, Florida Indago Research & Health Center Inc Recruiting Hialeah, Florida, United States, 33012 Future Care Solution, LLC Recruiting Miami, Florida, United States, 33165 Laszlo J Mate, MD, PA Recruiting North Palm Beach, Florida, United States, 33408 University of South Florida Not yet recruiting Tampa, Florida, United States, 33613 Bioclinica Research Recruiting The Villages, Florida, United States, 32162 United States, Massachusetts Boston Center Memory Recruiting Newton, Massachusetts, United States, 02459 United States, New Jersey The NeuroCognitive Institute Recruiting Mount Arlington, New Jersey, United States, 07856 United States, New York Parker Jewish Institute for Health Care & Rehabilitation Recruiting New Hyde Park, New York, United States, 11040 United States, North Carolina UNC Hospital Not yet recruiting Chapel Hill, North Carolina, United States, 27599 United States, Ohio Insight Clinical Trials LLC Recruiting Shaker Heights, Ohio, United States, 44122 United States, Pennsylvania Suburban Research Associates Recruiting Media, Pennsylvania, United States, 19063 Georgia Petre Sarajishvili Institute of Neurology LLC Recruiting Tbilisi, Georgia, 0112 Pineo Medical Ecosystem LTD Recruiting Tbilisi, Georgia, 0114 Health Institute LLC Recruiting Tbilisi, Georgia, 0160 S. Khechinashvili University Hospital LLC Recruiting Tbilisi, Georgia, 0179 收起 <<
NCT03121586	Schizophrenia	Phase 3	Recruiting	May 2021	-

匹莫范色林 /Pimavanserin 99%+

Pimavanserin 纯度/质量文件产品仅供科研

全球学术期刊中引用的产品

Pimavanserin 质控信息

Pimavanserin 生物活性

Pimavanserin 临床研究

Pimavanserin 参考文献

Pimavanserin 实验方案

Pimavanserin 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

匹莫范色林 /Pimavanserin 99%+

Pimavanserin 纯度/质量文件 产品仅供科研

全球学术期刊中引用的产品

Pimavanserin 质控信息

Pimavanserin 生物活性

Pimavanserin 临床研究

Pimavanserin 参考文献

Pimavanserin 实验方案

Pimavanserin 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

请登录您的专属账户

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

Pimavanserin 纯度/质量文件产品仅供科研